CompletedNot Applicable

Clinical Effects of Oral Trehalose In Patients With Spinocerebellar Ataxia 3

Malaysia13 participantsStarted 2018-03-07

Plain-language summary

There are no clinically established treatments which have been proven to delay the disease progression in spinocerebellar ataxia (SCA) 3. Most available treatments are only for symptom alleviation, and thus the majority of patients will eventually progress to needing and wheel chair and eventually bedridden. As trehalose appear to be potentially promising treatment in SCA, the investigators aim to conduct this study using oral trehalose in our genetically confirmed SCA 3 patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. DNA diagnosis of SCA 3 in the study subject of his/ her affected family member(s)
✓. Consent to participate in the study
✓. The age of 18 years and older

Exclusion criteria

✕. Unconfirmed SCA 3
✕. Concomitant disorder(s) that affect SARA and other ataxia measures used in this study
✕. Diabetes
✕. Malabsorption of trehalose underlies intolerance to mushrooms, since the lack of absorption results in diarrhoea and intestinal distress.
✕. Less than 18 years old

What they're measuring

scale of rating of ataxia (SARA) score months,

Timeframe: 2 monthly intervals for 6 months

SCA Functional Index Scores

Timeframe: 2 monthly intervals for 6 months

EQ5D3L - quality of life scores

Timeframe: 2 monthly intervals for 6 months

Trial details

NCT IDNCT04426149

SponsorNational University of Malaysia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-09-07

View on ClinicalTrials.gov More Spinocerebellar Ataxia 3 trials